| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2021 | Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study | Park K.; Haura E.B.; Leighl N.B.; Mitchell P.; Shu C.A.; Girard N.; Viteri S.; Han J.-Y.; Kim S.-W.; Lee C.K.; Sabari J.K.; Spira A.I.; Yang T.-Y.; Kim D.-W.; Lee K.H.; Sanborn R.E.; Trigo J.; Goto K.; Lee J.-S.; CHIH-HSIN YANG ; Govindan R.; Bauml J.M.; Garrido P.; Krebs M.G.; Reckamp K.L.; Xie J.; Curtin J.C.; Haddish-Berhane N.; Roshak A.; Millington D.; Lorenzini P.; Thayu M.; Knoblauch R.E.; Cho B.C. | Journal of Clinical Oncology | 187 | 157 | |
| 2011 | Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach | Salto-Tellez M.; Tsao M.-S.; JIN-YUAN SHIH ; Thongprasert S.; Lu S.; Chang G.-C.; Au J.S.-K.; Chou T.-Y.; Lee J.-S.; Shi Y.-K.; Radzi A.; Kang J.-H.; Kim S.-W.; Tan S.-Y.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 35 | 37 | |
| 2010 | Clinical impact of methicillin resistance on outcome of patients with Staphylococcus aureus infection: A stratified analysis according to underlying diseases and sites of infection in a large prospective cohort | Kang C.-I.; Song J.-H.; Chung D.R.; Peck K.R.; Ko K.S.; Yeom J.-S.; Kim S.-W.; Chang H.-H.; Kim Y.-S.; Jung S.-I.; Son J.S.; PO-REN HSUEH ; So T.M.K.; Lalitha M.K.; Yang Y.; Huang S.-G.; Wang H.; Lu Q.; Carlos C.C.; Perera J.A.; Chiu C.-H.; Liu J.-W.; Chongthaleong A.; Thamlikitkul V.; Van Pham H. | Journal of Infection | 44 | 42 | |
| 2013 | Common genetic determinants of breast-cancer risk in east asian women: A collaborative study of 23 637 breast cancer cases and 25 579 controls | Zheng W.; Zhang B.; Cai Q.; Sung H.; Michailidou K.; Shi J.; Choi J.-Y.; Long J.; Dennis J.; Humphreys M.K.; Wang Q.; Lu W.; Gao Y.-T.; Li C.; Cai H.; Park S.K.; Yoo K.-Y.; Noh D.-Y.; Han W.; Dunning A.M.; Benitez J.; Vincent D.; Bacot F.; Tessier D.; Kim S.-W.; Lee M.H, Lee J.W, Lee J.-Y.; Xiang Y.-B.; Zheng Y.; Wang W.; Ji B.-T.; Matsuo K.; Ito H.; Iwata H.; Tanaka H.; Wu A.H.; Tseng C.-C.; Van Den Berg D.; Stram D.O.; Teo S.H, Yip C.H, Kang I.N, Wong T.Y.; Shen C.-Y.; Yu J.-C.; CHIUN-SHENG HUANG ; Hou M.-F.; Hartman M.; Miao H.; Lee S.C, Putti T.C, Muir K.; Lophatananon A.; Stewart-Brown S.; Siriwanarangsan P.; Sangrajrang S.; Shen H.; Chen K.; Wu P.-E.; Ren Z.; Haiman C.A.; Sueta A.; Kim M.K, Khoo U.S, Iwasaki M.; Pharoah P.D.P.; Wen W.; Hall P.; Shu X.-O.; Easton D.F.; Kang D. | Human Molecular Genetics | 81 | 69 | |
| 2019 | Comparative genetic architectures of schizophrenia in East Asian and European populations | WEI J. CHEN ; Chen C.-Y.; Li Z.; Martin A.R.; Bryois J.; Ma X.; Gaspar H.; Ikeda M.; Benyamin B.; Brown B.C.; Liu R.; Zhou W.; Guan L.; Kamatani Y.; Kim S.-W.; Kubo M.; Kusumawardhani A.A.A.A.; CHIH-MIN LIU ; Ma H.; Periyasamy S.; Takahashi A.; Xu Z.; Yu H.; Zhu F.; Chen W.J.; Faraone S.; Glatt S.J.; He L.; Hyman S.E.; HAI-GWO HWU ; McCarroll S.A.; Neale B.M.; Sklar P.; Wildenauer D.B.; Yu X.; Zhang D.; Mowry B.J.; Lee J.; Holmans P.; Xu S.; Sullivan P.F.; Ripke S.; O’Donovan M.C.; Daly M.J.; Qin S.; Sham P.; Iwata N.; Hong K.S.; Schwab S.G.; Yue W.; Tsuang M.; Liu J.; Ma X.; Kahn R.S.; Shi Y.; Huang H.; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Indonesia Schizophrenia Consortium, Genetic REsearch on schizophreniA neTwork-China and the Netherlands (GREAT-CN) | Nature Genetics | 272 | 244 | |
| 2016 | Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium | Nakamura S.; Kwong A.; Kim S.-W.; Iau P.; Patmasiriwat P.; Dofitas R.; Aryandono T.; Hu Z.; CHIUN-SHENG HUANG ; Ginsburg O.; Rashid M.U.; Sarin R.; Teo S.-H. | Public Health Genomics | 39 | 32 | |
| 2020 | Does pemetrexed work in targetable, nonsquamous non-small-cell lung cancer? A narrative review | JIN-YUAN SHIH ; Inoue A.; Cheng R.; Varea R.; Kim S.-W. | Cancers | 9 | 6 | |
| 2019 | Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials | Cahn P.; Madero J.S.; Arribas J.R.; Antinori A.; Ortiz R.; Clarke A.E.; CHIEN-CHING HUNG ; Rockstroh J.K.; Girard P.-M.; Sievers J.; Man C.; Currie A.; Underwood M.; Tenorio A.R.; Pappa K.; Wynne B.; Fettiplace A.; Gartland M.; Aboud M.; Smith K.; Cassetti L.; David D.; Figueras L.; Losso M.; Lopardo G.; Lupo S.; Porteiro N.; Sánchez M.; Bloch M.; Cooper D.; Finlayson R.; Kelleher A.; Koh K.; Lewis D.; McMahon J.; Moore R.; Roth N.; Shields M.; De Wit S.; Florence E.; Goffard J.-C.; Demeester R.; Lacor P.; Vandercam B.; Vandekerckhove L.; Angel J.; Baril J.-G.; Conway B.; De Pokomandy A.; Szabo J.; Walmsley S.; Bouchaud O.; Chidiac C.; Delobel P.; Goujard C.; Katlama C.; Molina J.-M.; Pialoux G.; Philibert P.; Bogner J.; Esser S.; Krznaric I.; Lehmann C.; Spinner C.; Stellbrink H.-J.; Stephan C.; Stoehr A.; Barchi E.; Caramello P.; Castelli F.; Cattelan A.M.; D'Arminio Monforte A.; Di Biagio A.; Di Perri G.; Gori A.; Maggiolo F.; Menzaghi B.; Migliorino G.; Mussini C.; Penco G.; Puoti M.; Rizzardini G.; Gulminetti R.; Lazzarin A.; Quirino T.; Sighinolfi L.; Viale P.; Amaya Tapia G.; Andrade Villanueva J.; Granados Reyes E.R.; Perez Rios A.; Santoscoy Gomez M.; Den Hollander J.; Rijnders B.; Hidalgo J.A.; Hercilla Vasquez L.; Illescas L.; Olczak A.; Mansinho K.; Correia Pacheco P.P.; Teófilo E.; Saraiva da Cunha J.; Sarmento e Castro R.; Serrão R.; Arbune M.; Jianu C.; Oprea A.; Preotescu L.; Prisacariu L.-J.; Belonosova E.; Borodkina O.; Chernova O.; Gankina N.; Kizhlo S.; Kulagin V.; Kurina N.; Nagimova F.; Pokrovsky V.; Ryamova E.; Voronin E.; Yakovlev A.; Kaplan R.; Lee S.H.; Kim S.-W.; Kim S.-I.; Kim W.J.; Antela Lopez A.; Casado Osorio J.L.; Castaño Carracedo M.A.; De Los Santos Gil I.; Estrada Perez V.; Falco Ferrer V.; Force L.; Galinda Puerto M.J.; Garcia Deltoro M.; Gatell J.M.; Goenaga Sanchez M.A.; González Cordón A.; Knobel H.; Lopez Bernaldo de Quiros J.C.; Losa Garcia J.E.; Masia M.; Montero-Alsonso M.; Ocampo Hermida A.; Pasquau Liaño J.; Portilla Sogorb J.; Pulido Ortega F.; Rivera Roman A.; Santos Fernandez J.R.; Torres Perea R.; Troya Garcia J.; Viciana Fernandez P.; Calmy A.; Hauser C.; Fehr J.; Cheng S.-H.; Ko W.-C.; Lin H.-H.; Lu P.-L.; Tseng Y.-T.; Wang N.-C.; Wong W.-W.; Yang C.-J.; Arduino R.; Benson P.; Berhe M.; Bredeek F.; Brinson C.; Campbell T.; Crofoot G.; Cunningham D.; DeJesus E.; Dretler R.; Eron J.; Fife K.; Fichtenbaum C.; Flamm J.; Goldstein D.; Gupta S.; Hagins D.; Hoffman-Terry M.; Jayaweera D.; Kinder C.; Klein D.; McDonald C.; Mills A.; Nahass R.; Osiyemi O.; Overton E.; Parks D.; Prelutsky D.; Ramgopal M.; Schrader S.; Sha B.; Simon G.; Sims J.; Skiest D.; Slim J.; Tashima K.; Thedinger B.; Gazzard B.; Fox J.; Johnson M.; Kegg S.; Khoo S.; Mazhude C.; Orkin C.; Schembri G.; Ustianowski A.; GEMINI Study Team | The Lancet | 210 | 205 | |
| 2022 | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer | Jänne P.A.; Baik C.; Su W.-C.; Johnson M.L.; Hayashi H.; Nishio M.; Kim D.-W.; Koczywas M.; Gold K.A.; Steuer C.E.; Murakami H.; CHIH-HSIN YANG ; Kim S.-W.; Vigliotti M.; Shi R.; Qi Z.; Qiu Y.; Zhao L.; Sternberg D.; Yu C.; Yu H.A. | Cancer discovery | 66 | 53 | |
| 2020 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials | Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; CHIA-CHI LIN ; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. | The Lancet Oncology | 250 | 218 | |
| 2021 | Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations | Chang G.-C.; Lam D.C.-L.; Tsai C.-M.; Chen Y.-M.; JIN-YUAN SHIH ; Aggarwal S.; Wang S.; Kim S.-W.; Kim Y.-C.; Wahid I.; Li R.; Lim D.W.-T.; Sriuranpong V.; Chan R.T.-T.; Lorence R.M.; Carriere P.; Raabe C.; Cseh A.; Park K. | International Journal of Clinical Oncology | 1 | 1 | |
| 2016 | First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study | Park K.; CHONG-JEN YU ; Kim S.-W.; Lin M.-C.; Sriuranpong V.; Tsai C.-M.; Lee J.-S.; Kang J.-H.; Chan K.C.A.; Perez-Moreno P.; Button P.; Ahn M.-J.; Mok T. | JAMA Oncology | 185 | 157 | |
| 2022 | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial | Majem M.; Goldman J.W.; John T.; Grohe C.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.V.; Lu S.; Li S.; Lee K.Y.; Akewanlop C.; CHONG-JEN YU ; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Atagi S.; Zeng L.; Kulkarni D.; Medic N.; Tsuboi M.; Herbst R.S.; Wu Y.-L. | Clinical Cancer Research | 6 | 6 | |
| 2009 | High rate of reduced susceptibility to ciprofloxacin and ceftriaxone among nontyphoid Salmonella clinical isolates in Asia | Lee H.-Y.; Su L.-H.; Tsai M.-H.; Kim S.-W.; Chang H.-H.; Jung S.-I.; Park K.-H.; Perera J.; Carlos C.; Ban H.T.; Kumarasinghe G.; So T.; Chongthaleong A.; PO-REN HSUEH ; Liu J.-W.; Song J.-H.; Chiu C.-H. | Antimicrobial Agents and Chemotherapy | 96 | 87 | |
| 2020 | Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies | Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG ; Mitsudomi T.; Lee J.S. | Cancer Research and Treatment | 5 | 5 | |
| 2017 | Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component | CHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A. | Journal of Clinical Oncology | 415 | 426 | |
| 2020 | Osimertinib in resected EGFR-mutated non–small-cell lung cancer | Wu Y.-L.; Tsuboi M.; He J.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU ; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. | New England Journal of Medicine | 709 | 628 | |
| 2020 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study | Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG ; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. | The Lancet Oncology | 229 | 204 | |
| 2021 | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors | Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; CHIA-CHI LIN | JTO Clinical and Research Reports | 3 | 0 | |
| 2021 | A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer | Wu Y.-L.; Tsuboi M.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU ; De Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. | Future Oncology | 3 | 1 | |
